MedTrace Logo

Oocyte Vitrification Aided With Latrunculin A

NCT03678571 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2019-07-16

No results posted yet for this study

Summary

Using cytoskeleton Stabilizer the Latrunculin A would improve the outcome of oocyte vitrification

Conditions

Interventions

OTHER

Latrunculin A supplemented vitrification medium

Vitrification of human oocyte in medium supplemented with Latrunculin A

Sponsors & Collaborators

  • Banoon IVF Center

    collaborator OTHER

  • Ibn Sina Hospital

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-25
Primary Completion
2019-07-01
Completion
2019-07-15

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03678571 on ClinicalTrials.gov